Ibrunat
Brand Name: Ibrunat®
Composition: Ibrutinib Capsules 140mg
Form / Presentation: Capsules
Manufacturer: NATCO
Product Description
Medical Info
Ibrunat® is a high-quality pharmaceutical formulation containing 140 mg of Ibrutinib, manufactured under strict quality compliance by NATCO. As a potent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), it serves as a critical targeted therapy in modern oncology. It is primarily indicated for the treatment of patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). By irreversibly binding to BTK, Ibrunat® effectively disrupts the signaling pathways that promote malignant B-cell proliferation and survival, offering clinicians a reliable option for precise therapeutic disease management.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
